Press Releases

• Aditxt: Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market More
• Biocom California: 10th Annual Life Science Catalyst Award Winners More
• Biomea Fusion: First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist More
• BridgeBio: Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study More More
• BridgeBio Oncology Therapeutics: Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia More
• Guardant Health and Zephyr AI: Partnership to Unlock Drug Response Predictions and Biomarker Insights More
• Innovent: Mazdutide Shows Superiority in Glycemic Control With Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 More
• Jupiter Endovascular: Positive Results From SPIRARE I First-in-human Study Presented at TCT 2025 More
• Kivu Bioscience: Appoints Sophia Randolph, M.D., Ph.D., as Chief Medical Officer More
  
• Kyverna Therapeutics: Highlights Potential of KYV-101 in Rheumatoid Arthritis With Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 More
• ORIC Pharmaceuticals: Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors More
• Quanta Therapeutics: Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients With Advanced Solid Tumors More
• RAPT Therapeutics: Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients ith Food Allergies More
• Revolution Medicines: RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer More

Financial News

• Exclusive VC Funding Data from BYTE51, with Special Big4Bio Pricing More
• How Akero Therapeutics Saved a Multibillion-Dollar Biotech Deal More* More*
• MapLight Therapeutics: Pricing of Initial Public Offering More More More* More*
• More on Eli Lilly Buying Cash-Strapped Adverum for Its Phase 3-Stage Eye Disease Gene Therapy More More*
• Nurix Therapeutics: Closing of $250.0 Million Registered Offering of Common Stock More
• QT Imaging: 3:1 Reverse Stock Split Market Effective on October 24, 2025 More
• Vivani Medical: Pricing of Common Stock Offering More
  

Media/Misc Coverage

• In Push for New Infection-Fighting Drugs, Genentech’s AI Seeks No Resistance More*
  
• Subscribe to LifeSci Startup for Updates on US Startups More

Companies

Career Center

• Elevating Executive Presence: A Blueprint for Life Sciences and Biotech Leaders More
• CEO’s Perspective: Big Moves Come with Big Responsibility More
• CEO’s Perspective: The High Cost of Job Hopping More
• ICYMI: The Power of Peer Learning - Why Even Top Biotech Leaders Need Mentorship More
• Shape’s Former CSO Picks Up Tech Role at Moderna; Lilly Reels In Peter Marks More*
• What’s Next in Precision Medicine: Leadership Challenges and Opportunities More

• 15th Annual PODD Conference Oct 27-28
• New Jersey Life Sciences & Biotech Conference Oct 28
• Biocom California CEO Summit (Los Angeles) Oct 29
• Pantheon 2025 Nov 6
• BIO-Europe 2025 Nov 11-12
• Copay, Reimbursement and Access Congress (Save 10% with VIP code: 25B4B10) Nov 18-20
• Pharma/Biotech Gross-To-Net Summit (Save 10% with VIP code: 25B4B10) Nov 18-20
• Patient Support Services Congress (Save 10% with VIP code: 25B4B10) Nov 20-21
• Compounding Pharmacy Compliance (Save 10% with VIP code: 25B4B10) Dec 9-10
• Trade and Channel Strategies (Save 10% with VIP code: 25B4B10) Dec 9-11
  
• Advancing Drug Development Forum Dec 11

SF Bay Sponsors